EGFR and non-small cell lung carcinoma: In the context of therapeutic alternatives for lung conditions, the EMERGING‐CTONG 1103 trial demonstrated that neoadjuvant erlotinib can improve the outcomes in Stage IIIA‐N2 NSCLC patients with EGFR mutations, presenting better tolerability over gemcitabine‐cisplatin chemotherapy with postoperative therapy showing no severe adverse events [260].